HER2-Negative and CLDN18.2-Positive Gastric
Gastric and gastroesophageal junction (GEJ) adenocarcinomas are aggressive malignancies with limited treatment options. Recent advancements have identified CLDN18.2 as a promising biomarker in patients with HER2-negative tumors, offering new therapeutic possibilities. Understanding HER2-Negative Gastric Cancer HER2-negative gastric cancer refers to tumors that lack overexpression of the human epidermal growth factor receptor 2 (HER2) protein. These